Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access of Ibalizumab + OBR in MDR HIV-1
NCT02707861Phase 3Completed
- Sponsor
- TaiMed Biologics
- Start
- Mar 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ibalizumab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by TaiMed Biologics. Started Mar 2016; status: completed.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02707861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707861.